C.-H. Köhne

Clinical determinants of survival in patients with 5-fluorouracil- based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients

C.-H. Köhne, David Cunningham, Francesco Di Costanzo et al. · Annals of Oncology · 2002 · 456 citations · Full text

Clinical Determinants, Surgical Oncology, Multivariate Analysis +8

Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial

Eric Van Cutsem, Marek P. Nowacki, István Láng et al. · Journal of Clinical Oncology · 2007 · 314 citations

Pathology, Pharmacotherapy, Crystal Trial +17

Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials

Gunnar Folprecht, David Cunningham, Paul J. Ross et al. · Annals of Oncology · 2004 · 256 citations · Full text

5-Fluorouracil-based Chemotherapy, Elderly Patients, Gastrointestinal Oncology +6

FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer

Carsten Bokemeyer, C.-H. Köhne, Fortunato Ciardiello et al. · European Journal of Cancer · 2015 · 241 citations · Full text

Gastrointestinal Oncology, Medicine, Pathology +6

Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma

Gunnar Folprecht, Manfred P. Lutz, Patrick Schöffski et al. · Annals of Oncology · 2005 · 233 citations · Full text

Oncology, Medicine, Colorectal Cancer +7